BiVictriX Therapeutics Plc announced that it has identified a development lead for its BVX001 programme. The Lead was developed using BiVictriX's proprietary Bi-Cygni® approach, which aims to generate the next-generation of Antibody Drug Conjugates ("ADCs") with superior cancer selectivity. The Lead was selected based on promising in vitro potency and cancer cell selectivity data, together with encouraging data reported from a panel of ex-vivo safety assays using healthy human cells.

The Lead, together with backup candidates, will now betaken forward into a panel of in vivo models. These will include models of Acute Myeloid Leukaemia to investigate the optimum dose of the molecule. In addition, the Lead will be assessed in safety models providing indicative safety data for the programme.

Results from these experiments, in addition to the data already obtained, will support manufacturing preparations and guide future clinical trials.